386 related articles for article (PubMed ID: 34305910)
1. Immune Checkpoint Inhibitors in Human Glioma Microenvironment.
Ghouzlani A; Kandoussi S; Tall M; Reddy KP; Rafii S; Badou A
Front Immunol; 2021; 12():679425. PubMed ID: 34305910
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes.
Qi Y; Liu B; Sun Q; Xiong X; Chen Q
Front Immunol; 2020; 11():578877. PubMed ID: 33329549
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
4. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Zhang N; Wei L; Ye M; Kang C; You H
Front Immunol; 2020; 11():592612. PubMed ID: 33329578
[TBL] [Abstract][Full Text] [Related]
5. TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas.
Chen R; Wang X; Dai Z; Wang Z; Wu W; Hu Z; Zhang X; Liu Z; Zhang H; Cheng Q
Front Immunol; 2021; 12():713757. PubMed ID: 34712225
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory Effects of Tryptophan Metabolism in the Glioma Tumor Microenvironment.
Xu Y; Zhang H; Sun Q; Geng R; Yuan F; Liu B; Chen Q
Front Immunol; 2021; 12():730289. PubMed ID: 34659216
[TBL] [Abstract][Full Text] [Related]
7. The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.
Ghouzlani A; Lakhdar A; Rafii S; Karkouri M; Badou A
Sci Rep; 2021 Nov; 11(1):21504. PubMed ID: 34728682
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
9. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma.
Foster A; Nigam S; Tatum DS; Raphael I; Xu J; Kumar R; Plakseychuk E; Latoche JD; Vincze S; Li B; Giri R; McCarl LH; Edinger R; Ak M; Peddagangireddy V; Foley LM; Hitchens TK; Colen RR; Pollack IF; Panigrahy A; Magda D; Anderson CJ; Edwards WB; Kohanbash G
EBioMedicine; 2021 Sep; 71():103571. PubMed ID: 34530385
[TBL] [Abstract][Full Text] [Related]
10. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
12. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
13. Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas.
Bockmayr M; Klauschen F; Maire CL; Rutkowski S; Westphal M; Lamszus K; Schüller U; Mohme M
Cancer Immunol Res; 2019 Sep; 7(9):1401-1411. PubMed ID: 31266783
[TBL] [Abstract][Full Text] [Related]
14. Tumour immune landscape of paediatric high-grade gliomas.
Ross JL; Velazquez Vega J; Plant A; MacDonald TJ; Becher OJ; Hambardzumyan D
Brain; 2021 Oct; 144(9):2594-2609. PubMed ID: 33856022
[TBL] [Abstract][Full Text] [Related]
15. T lymphocyte-targeted immune checkpoint modulation in glioma.
Kelly WJ; Giles AJ; Gilbert M
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051289
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.
Arrieta VA; Dmello C; McGrail DJ; Brat DJ; Lee-Chang C; Heimberger AB; Chand D; Stupp R; Sonabend AM
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647828
[TBL] [Abstract][Full Text] [Related]
17. Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
Zhang QJ; Luan JC; Song LB; Cong R; Ji CJ; Zhou X; Xia JD; Song NH
Front Immunol; 2021; 12():657575. PubMed ID: 33936087
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
[TBL] [Abstract][Full Text] [Related]
20. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
